论文部分内容阅读
对急性血管阻塞进行溶血纤疗法,往往与出血危险相关连。因此,链激酶和尿激酶用于溶解血栓时,要选择一定的适应症,并注意相应的禁忌症。临床使用基因技术生产的人体rt-PA(重组组织纤维蛋白溶酶原激活剂),似乎能降低出血并发症的发生率。与链激酶相反,rt-PA只激活与血纤维结合的纤维蛋白溶酶原,而对游离的纤维蛋白溶酶原无影响;因而对血栓的选择性较高,而不引起系统性纤维蛋白溶解作用。 rt-PA获准在急性心肌梗塞发生16小时内用于溶血纤治疗,推荐剂量为100mg;
Hemolytic fibrinolytic therapy of acute vascular obstruction is often associated with the risk of bleeding. Therefore, streptokinase and urokinase for the dissolution of thrombosis, we must choose a certain indications, and pay attention to the corresponding contraindications. Human rt-PA (recombinant tissue plasminogen activator) produced clinically using genetic technology seems to reduce the incidence of bleeding complications. In contrast to streptokinase, rt-PA activates only the fibrin-bound plasminogen without any effect on free plasminogen; thus, it has a higher selectivity for thrombus without causing systemic fibrinolysis effect. rt-PA approved for the treatment of hemolytic fibrosis within 16 hours of onset of acute myocardial infarction, the recommended dose of 100mg;